UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 67

of 'Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults'

67
TI
Prognostic factors of Guillain-Barrésyndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-BarréStudy Group.
AU
Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der MechéFG
SO
Neurology. 1999;53(3):598.
 
OBJECTIVE: To determine the influence of clinical, laboratory, and electrodiagnostic factors on the prognosis of Guillain-Barrésyndrome (GBS).
BACKGROUND: Identification of prognostic factors may lead to better selection of patients with a poor prognosis for new therapeutic trials.
METHODS: The authors studied 147 patients with GBS who participated in the Dutch GBS trial comparing the effect of IV immunoglobulins with plasma exchange (PE). Outcome was measured at 8 weeks because half of the patients had recovered independent locomotion by then and at 6 months, the endpoint of the study.
RESULTS: Multivariate logistic regression revealed the following factors predicting outcome (inability to walk independently) at 8 weeks: a preceding gastrointestinal illness (yes, no), age (>or =50,<50 years), Medical Research Council sum score (<40,>or =40) at the start of treatment, and-described for the first time-a recent cytomegalovirus (CMV) infection (yes, no). At 6 months, the same clinical factors were found, but an initial rapid progression of weakness also appeared to be a prognostic factor. Analysis of treatment interactions revealed that the effect of diarrhea was more pronounced in the PE-treated group.
CONCLUSIONS: The main predictors of outcome in GBS are clinical factors. Diarrhea is an important poor predictor of outcome, especially for the PE-treated group, and a recent CMV infection predicts delayed early recovery.
AD
Department of Neurology, University Hospital Dijkzigt/Dr. Daniel den Hoed Cancer Center and Erasmus University, Rotterdam, The Netherlands.
PMID